Taken together, these studies suggest that IGF2BP2 inhibitors have high therapeutic potential and that with further refinement the application of these compounds would allow us to effectively reduce PLK1 protein levels and ultimately suppress PLK1-overexpressing cancer cells and tumors. The gene discussed is IGF2BP2; the disease is cancer.